Navigation Links
Matthew B. Potter Joins Pressure BioSciences, Inc. as Vice President of Sales
Date:3/11/2008

SOUTH EASTON, Mass., March 11 /PRNewswire-FirstCall/ -- Pressure BioSciences, Inc. (Nasdaq: PBIO) ("PBI") today announced that Matthew B. Potter has joined PBI's senior executive management team as Vice President of Sales. Mr. Potter brings with him nearly twenty years of experience in sales and sales management at a number of leading life sciences companies. Mr. Potter will oversee PBI's seven US-based, regional sales directors and will be responsible for driving the Company's commercialization of its novel and patented pressure cycling technology (PCT) product line.

Mr. Richard T. Schumacher, PBI's Founder, President, and CEO stated: "This is an important and exciting time for our Company, as our efforts in 2008 are clearly focused on both the development of market awareness for PCT and on the expansion of our small but growing customer base. To this end, we believe that Matt's background and management style is a not only a great fit with our team, but should also help to accelerate our PCT commercialization plan. We consider ourselves very fortunate to have someone of Matt's caliber join our management team."

Mr. Schumacher continued: "In addition to bringing significant sales and sales leadership experience to PBI, the hiring of Matt allows Dr. Nathan Lawrence, who previously led both sales and marketing, to focus all of his efforts on marketing, collaboration support, distribution outside of the United States, and liaison activities between collaborators and our scientific and engineering teams. This new focus for Dr. Lawrence will allow us to align our sales and marketing efforts in a manner that supports our Company's transition to a fully commercial operation in 2008."

About Matthew B. Potter

Over his career, Mr. Potter has been a Sales Manager at Pharmacia Biotech; National Sales Director at Visible Genetics; Director, Sales and Marketing at MicroCal, LLC; National Sales Manager, Key Accounts -- Pharma at Qiagen, Inc; and Vice President of Sales and Marketing at Abcam, Inc. Before his transition into sales, Mr. Potter was a researcher at the Worcester Foundation for Experimental Biology. Mr. Potter holds a BA in Biology from Clark University and an MBA from Assumption College, both located in Worcester, MA.

Mr. Potter commented: "In over 19 years of selling products into the research marketplace for the analysis of nucleic acids, proteins, and small molecules, one issue -- how to achieve high quality extraction of bio- molecules prior to analysis -- nearly always rose to the top. This was always a key issue, and to that end, I believe strongly that the PCT Sample Preparation System answers many of the sample preparation problems that researchers encounter, and offers unique advantages to customers looking to extract DNA, RNA, proteins, and small molecules from a wide variety of biological samples. PBI has a dedicated and talented group of people throughout the organization, and I look forward to working with them -- and in particular our newly hired field sales organization -- to drive this technology into the marketplace."

About Pressure BioSciences, Inc.

Pressure BioSciences, Inc. (PBI) is a publicly traded company focused on the development of a novel, enabling technology called pressure cycling technology (PCT). PCT uses cycles of hydrostatic pressure between ambient and ultra-high levels (up to 35,000 psi and greater) to control bio-molecular interactions. PBI currently holds 13 US and 6 foreign patents covering multiple applications of PCT in the life sciences field, including in such areas as genomic and proteomic sample preparation, pathogen inactivation, the control of chemical reactions, immunodiagnostics, and protein purification.

Forward Looking Statements

Statements contained in this press release regarding the Company's intentions, hopes, beliefs, expectations, or predictions of the future are "forward-looking'' statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward looking statements include the expectation that Mr. Potter will be successful in helping to drive the acceptance and commercialization of PCT and the PCT Sample Preparation System into the marketplace, Dr. Lawrence will now be able to refocus his efforts in a manner that the Company believes will support the transition to full commercialization, and Mr. Potter's belief that the PCT Sample Preparation System offers unique advantages in bio-molecule extraction. These statements are based upon the Company's current expectations, forecasts, and assumptions that are subject to risks, uncertainties, and other factors that could cause actual outcomes and results to differ materially from those indicated by these forward-looking statements. These risks, uncertainties, and other factors include, but are not limited to, possible difficulties or delays in the implementation of the Company's strategies that may adversely affect the Company's continued commercialization of its PCT Sample Preparation System; future revenues may not meet expectations due to the possible failure of the Company's products to achieve commercial acceptance, changes in customers' needs and technological innovations, and expenses that may be higher than anticipated due to unforeseen cost increases; if the Company's expenses are higher than anticipated or if the Company's revenues do not increase, the Company may not have sufficient cash to support its planned activities and the Company may be unable to obtain financing on acceptable terms; the Company's new external sales force, now directed by Mr. Potter, may not be successful in selling the Company's PCT product line because scientists may not perceive the advantages of PCT over other sample preparation methods; and the Company may be unable to develop new PCT-related products that are perceived by potential customers as having advantages over current technologies and techniques or achieve commercial acceptance. Additional risks and uncertainties that could cause actual results to differ materially from those indicated by these forward looking statements are discussed under the heading "Risk Factors" in the Company's Annual Report on Form 10-KSB for the year ended December 31, 2006 and other reports filed by the Company from time to time with the SEC. The Company undertakes no obligation to update any of the information included in this release, except as otherwise required by law.

Visit us at our website http://www.pressurebiosciences.com

Investor Contacts:

Richard T. Schumacher, President & CEO

Edward H. Myles, Senior Vice President of Finance & CFO

Pressure BioSciences, Inc.

(508) 230-1828 (T)


'/>"/>
SOURCE Pressure BioSciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Genstructs Andrea Matthews Selected for Mass High Techs People to Watch Under 30
2. Cerimon Pharmaceuticals Names Matthew J. Meyer its General Counsel and Vice President of Business Development and Licensing
3. Cord Blood America CEO Matthew Schissler Interviewed by BIONOVA, Greeces Leading Biotech Magazine
4. Roche Joins Forces With Enon Tabernacle Baptist Church to Provide Free Hepatitis C Testing to the Community
5. Ralf Rosskamp, M.D. Joins Biodels Scientific Advisory Board
6. Hank Plain Joins Morgenthaler Ventures as Partner
7. Legendary Earvin Magic Johnson Joins AFL/Signalife Cardiovascular Protection Team
8. Senior Research Analyst Richard Evans Joins AVOS Life Sciences
9. Dan Broderick Joins Prolog Ventures as Partner
10. Ingenuity Systems Joins Biomarkers Consortium
11. Founder of ILEX Oncology and Triton Biosciences, Richard Love, Joins Board of Directors of Cell Therapeutics, Inc. (CTI)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... MONICA, Calif. , June 23, 2016  The Prostate Cancer Foundation ... pioneer increasingly precise treatments and faster cures for prostate cancer. Members of the ... institutions across 15 countries. Read More About the Class ... ... ...
(Date:6/23/2016)... , June 23, 2016   EpiBiome , a ... $1 million in debt financing from Silicon Valley Bank ... automation and to advance its drug development efforts, as ... facility. "SVB has been an incredible strategic ... services a traditional bank would provide," said Dr. ...
(Date:6/23/2016)... ON (PRWEB) , ... June 23, 2016 , ... STACS ... DNA Technical Leader at the Arkansas State Crime Laboratory, has joined STACS DNA as ... the STACS DNA team,” said Jocelyn Tremblay, President and COO of STACS DNA. “In ...
(Date:6/23/2016)... 23, 2016 Apellis Pharmaceuticals, Inc. today ... trials of its complement C3 inhibitor, APL-2. The ... ascending dose studies designed to assess the safety, ... injection in healthy adult volunteers. Forty ... a single dose (ranging from 45 to 1,440mg) ...
Breaking Biology Technology:
(Date:6/2/2016)...   The Weather Company , an IBM Business (NYSE: ... capability in which consumers will be able to interact with ... via voice or text and receive relevant information about the ... Marketers have long sought an advertising solution that can create ... relevant and valuable; and can scale across millions of interactions ...
(Date:6/1/2016)... , June 1, 2016 Favorable ... Election Administration and Criminal Identification to Boost Global Biometrics ... recently released TechSci Research report, " Global Biometrics Market ... Competition Forecast and Opportunities, 2011 - 2021", the global ... by 2021, on account of growing security concerns across ...
(Date:5/20/2016)... 20, 2016  VoiceIt is excited to announce ... By working together, VoiceIt and VoicePass ... and VoicePass take slightly different approaches to voice ... security and usability. ... new partnership. "This marketing and technology ...
Breaking Biology News(10 mins):